Method of controlling tight blood glucose by somatostatin receptor antagonists
View Patent ↗The present disclosure provides methods and uses for controlling tight blood glucose levels in a subject comprising administering an effective amount of a somatostatin inhibitor. The present disclosure provides methods and uses for treating or preventing hypoglycemia in a subject comprising administering an effective amount of a somatostatin inhibitor.
1. A method of controlling tight blood glucose levels comprising administering an effective amount of a somatostatin receptor (SSTR) antagonist to a subject in need thereof, wherein the subject has idiopathic hypoglycemia or an insulinoma tumor or the subject is a diabetic subject with insulin-induced hypoglycemia.
2. The method of claim 1 for treating hypoglycemia.
3. The method of claim 1 , wherein the subject is an insulin-dependent diabetic.
4. The method of claim 3 , wherein the subject has Type I diabetes.
5. The method of claim 3 , wherein the subject has Type II diabetes.
6. The method of claim 1 , wherein the subject suffers from idiopathic hypoglycemia.
7. The method of claim 1 , wherein the subject has an insulinoma tumor.
8. The method of claim 1 , wherein the somatostatin receptor antagonist is a peptide antagonist of SSTR or a pharmaceutically acceptable salt thereof.
9. The method of claim 1 , wherein the somatostatin receptor antagonist is a peptide antagonist of SSTR2 or a pharmaceutically acceptable salt thereof.
10. The method of claim 1 , wherein the somatostatin receptor antagonist is an antagonist of SSTR having a peptide as listed in any one of peptide no.s:27-436 of Table 6 or a pharmaceutically acceptable salt thereof.
11. The method of claim 1 , wherein the somatostatin receptor antagonist is an antagonist of SSTR having a peptide as listed in any one of peptide no.s:27-120 of Table 6 or a pharmaceutically acceptable salt thereof.
12. The method of claim 1 , wherein the somatostatin receptor antagonist is an antagonist of SSTR having a peptide sequence as shown in SEQ ID NOs:27-34 or a pharmaceutically acceptable salt thereof.
13. The method of claim 1 , wherein the antagonist of SSTR is the cyclic-octapeptide as shown in SEQ ID NO:28 or a pharmaceutically acceptable salt thereof.
14. The method of claim 1 , wherein the somatostatin receptor antagonist is an antibody against a somatostatin receptor.
15. The method of claim 14 , wherein the antibody against the somatostatin receptor binds to a somatostatin receptor having the amino acid sequence as shown in any one of SEQ ID NOs:5-14.
16. The method of claim 14 , wherein the antibody against the somatostatin receptor binds to a somatostatin receptor 2 having the amino acid sequence as shown in SEQ ID NO:7 or SEQ ID NO:8.
17. The method of claim 1 , wherein the subject is a mammal.
18. The method of claim 17 , wherein the mammal is human.
19. The method of claim 1 , wherein the subject has a blood glucose level of less than 4.0 mM.